

Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT05743400

Status	RECRUITING
Phase	Phase 4
Sponsor	Hospices Civils de Lyon
Enrollment	35 participants

Key Eligibility Criteria

Inclusion (6)

- Patient receiving Thymoglobulin therapy as part of a first HSCT
- Age e 2 years
- Lansky or karnofsky score e 50%.
- Enrolled in a social security plan
- Patient 18 years of age or older who is informed and has consented to participate in the study or minor patient whose parents/guardians have been informed and have given consent for the minor patient to participate in the study
- ... and 1 more (see full listing online)

Exclusion (7)

- Patient having received serotherapy (Thymoglobulin® or other) within 3 months before this HSCT
- Patient receiving another serotherapy during conditioning (Campath®)
- Patients with uncontrolled acute or chronic infections for which any form of immunosuppression would be contraindicated
- Known hypersensitivity to Thymoglobulin®.
- Pregnant or lactating women
- ... and 2 more (see full listing online)

Locations (2 total)

Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France
Centre Hospitalier Lyon Sud, Pierre-Bénite, France